期刊
BRITISH JOURNAL OF CANCER
卷 106, 期 5, 页码 1004-1010出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2012.19
关键词
IGF-I; IGFBP-3; pancreatic cancer; cohort study
类别
资金
- Deutsche Forschungsgemeinschaft [793]
- European Commission (DG-SANCO)
- International Agency for Research on Cancer
- Danish Cancer Society (Denmark)
- LigueContre le Cancer
- InstitutGustaveRoussy
- MutuelleGenerale de l'EducationNationale
- Institut National de la Sante et de la RechercheMedicale (INSERM
- France)
- Deutsche Krebshilfe
- Deutsches Krebsforschungszentrum (DKFZ)
- Federal Ministry of Education and Research (Germany)
- Ministry of Health and Social Solidarity
- Stavros Niarchos Foundation
- Hellenic Health Foundation (Greece)
- Italian Association for Research on Cancer (AIRC)
- National Research Council (Italy)
- Dutch Ministry of Public Health
- Welfare and Sports (VWS)
- Netherlands Cancer Registry (NKR)
- LK Research Funds
- Dutch Prevention Funds
- Dutch ZON (ZorgOnderzoek Nederland)
- World Cancer Research Fund (WCRF)
- Statistics Netherlands (The Netherlands)
- Nordforsk
- Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway)
- Health Research Fund (FIS)
- Regional Governments of Andalucia
- Asturias
- Basque Country
- Murcia and Navarra
- ISCIII RETIC (Spain) [RD06/0020]
- Swedish Cancer Society
- Swedish Scientific Council
- Regional Government of Skane and Vasterbotten (Sweden)
- Cancer Research UK
- Medical Research Council
- Stroke Association
- British Heart Foundation
- Department of Health, Food Standards Agency
- Wellcome Trust (United Kingdom)
- [ERC-2009-AdG 232997]
- Cancer Research UK [14136] Funding Source: researchfish
- Medical Research Council [MC_U106179471, G0801056B, G0401527, G1000143] Funding Source: researchfish
- Novo Nordisk Fonden [NNF10OC1013267] Funding Source: researchfish
BACKGROUND: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. METHODS: Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables. RESULTS: Neither circulating levels of IGF-I (OR = 1.21, 95% CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (OR = 1.00, 95% CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR = 1.22, 95% CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR = 1.72, 95% CI 1.05-2.83; P-interaction = 0.154). CONCLUSION: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk. British Journal of Cancer (2012) 106, 1004-1010. doi:10.1038/bjc.2012.19 www.bjcancer.com Published online 7 February 2012 (C) 2012 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据